Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive
Conditions
Interventions
None listed
Sponsors
R Saravanabhavan
Eligibility
Inclusion criteria
Inclusion criteria: Patients who are already under the treatment for Chronic Myeloid Leukaemia Patients of both male and female sexes are included Age range of the patients should be 18 to 85 should have completed 18 years before taking part in the study Patients in any stage of the CML are included
Exclusion criteria
Exclusion criteria: Patients with concurrent malignancies other than CML 2. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive therapy. Hence, patients with any of the following diseases other than CML who are considered not suitable by the physician will not be recruited for this research project: Cardiovascular Disease Fluid Retention, Bone Marrow suppression Gastrointestinal Disorders Hepatic Impairment Hypothyroidism Renal Impairmen Patients treated with any other chemotherapeutic drugs in addition to imatinib Female patients who are pregnant Patients who have not completed 18 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of SNPs Genetic Biomarkers that are associated with the Imatinib clinical response Toxicity and Resistance Timepoint: 3rd month 6th month 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of SNPs Genetic Biomarkers that are associated with the Imatinib ResistanceTimepoint: Third Month 6th month one year | — |
Countries
India
Contacts
Public ContactR Saravanabhavan
Vels University
Outcome results
None listed